ANNALS OF SURGICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-07-24 匿名用户

提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回

1 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-07-11 匿名用户

原创要视觉摘要

2 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-07-11 匿名用户

要视觉摘要

1 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-05-12 xiaoat2015 来自天津

文章发表总是Awaiting Disclosure Form

5 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2024-12-28 ms5000000711521518 来自新疆

请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审

25 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-04-09 ms1000000534985624 来自江苏省

求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！

23 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-03-25 ms9000001679751169 来自湖北省

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：胸部肿瘤
经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊

35 7 举报

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2021-03-26 六公子

审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0
偏重的研究方向：胸外科;肿瘤学;肺癌
经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。

152 17 举报

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2024-06-17 ms6000000157217108 来自吉林省

请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了

96 17 举报

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272961, encodeId=61ae22e296171, content=原创要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:16:31 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272960, encodeId=c72c22e29608e, content=要视觉摘要, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 15:01:33 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2264676, encodeId=61ba22646e6c3, content=文章发表总是Awaiting Disclosure Form, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=546b1615662, createdName=xiaoat2015, createdTime=Mon May 12 15:37:16 CST 2025, time=2025-05-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2257643, encodeId=782d225e64306, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：胸部肿瘤 经验分享：去年十月投的稿，圣诞节前一审结束，给了大修，两周后我提交修改稿，到3.24给了reject，拒稿理由是很感兴趣但是目前收稿量远大于发表量，实在太坑，拖了整整半年多，着急毕业的实在不建议这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb89384566, createdName=ms9000001679751169, createdTime=Tue Mar 25 12:21:00 CST 2025, time=2025-03-25, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0 偏重的研究方向：胸外科;肿瘤学;肺癌 经验分享：去年十一月底投稿，今年一月初收到major revision的decision letter，给了11条非常中肯的意见，花了20天修改resubmit后过了一月收到minor revision的decision letter，给了两条意见，花了10天修改提交后只过了8天就再次收到了minor revision的decision letter，又提了两条意见，花了9天再次修改提交后，只过了4天就accept了。这是我第一次投SCI，前后经历了一次大修，两次小修，一共花了三月多不到四月的时间。杂志审稿非常迅速，给编辑发的邮件回复得也很及时，reviewer每次的意见也非常中肯，没有版面费，accept后还被邀请写Author Reflections，非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2024-04-30 新来的小李来自贵州省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤外科
经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多

103 8 举报

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务